Welcome to our dedicated page for OSR Holdings SEC filings (Ticker: OSRH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OSR Holdings, Inc. (NASDAQ: OSRH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. OSR Holdings is a global healthcare holding company engaged through its subsidiaries in immuno-oncology, regenerative biologics, and medical device technologies, and its filings offer detailed information on corporate transactions, governance, financing arrangements, and listing status.
Investors can review Form 8-K current reports where OSR Holdings describes material events such as share exchange agreements, licensing term sheets, financing amendments, and notices from The Nasdaq Stock Market LLC. For example, 8-K filings outline the Share Exchange Agreement under which OSR Holdings Co., Ltd. will acquire all issued and outstanding shares of Woori IO Co., Ltd., making Woori IO a wholly owned subsidiary, and describe Woori IO’s non-invasive biosensing technology for glucose monitoring. Other 8-Ks detail Vaximm AG’s non-binding and binding term sheets with BCM Europe AG for potential global licensing of the VXM01 oral cancer immunotherapy platform, including exclusivity periods and proposed financial structures.
The company’s proxy materials, such as the Definitive Proxy Statement on Schedule DEF 14A, set out proposals for director elections, advisory votes on executive compensation, share-based incentive plans under the 2025 Omnibus Incentive Plan, and approvals under Nasdaq Listing Rule 5635(d) for potential issuances of common stock or related securities in excess of 20% of outstanding shares. These documents also confirm OSR Holdings’ status as an emerging growth company and describe its principal executive offices and meeting logistics.
Filings also include disclosures related to Nasdaq listing compliance, such as the Form 8-K describing receipt of a minimum bid price deficiency notice under Listing Rule 5550(a)(2), along with the company’s stated intention to monitor its share price and consider options to regain compliance. Additional 8-Ks cover amendments to a Note Purchase Agreement and Common Stock Purchase Warrant with White Lion Capital, LLC, clarifying exchange caps and shareholder approval requirements.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key terms, conditions, and implications for OSR Holdings’ capital structure and strategic direction. Users can quickly scan material agreements, governance proposals, and listing updates, and then drill down into the full-text filings for deeper analysis, including exhibits such as term sheets, annexes, and press releases incorporated by reference.
OSR Holdings, Inc. filed an 8-K reporting the results of a shareholder vote on director elections. Several nominees received overwhelming affirmative votes and were elected, while two nominees received large negative vote totals and were not elected. For example, Jun Chul Whang received 13,321,765 votes for and 3,926 against and was elected. Seng Chin Mah received 13,321,806 for and 3,885 against and was elected. Two nominees, Jin Whan Park (451,054 for; 12,874,637 against) and Phil Geon Lee (451,095 for; 12,874,596 against), were not elected. The filing supplies vote counts and final election outcomes for each listed nominee.
OSR Holdings, Inc. reported that it received a Nasdaq notice on September 5, 2025 stating its common stock no longer meets the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for 30 consecutive business days. The company’s stock traded below this level for that full period, triggering the deficiency.
The notice does not immediately affect trading, and OSR Holdings’ common stock and warrants will continue to trade on the Nasdaq Capital Market under the symbols OSRH and OSRHW. The company has 180 calendar days, until March 4, 2026, to regain compliance by maintaining a closing bid price of $1.00 or more for at least ten consecutive business days.
If OSR Holdings does not regain compliance by March 4, 2026, it may qualify for an additional 180‑day period if it meets other Nasdaq listing standards and formally notifies Nasdaq of its plan to cure the deficiency, potentially including a reverse stock split. If it cannot secure the extra period or still fails to comply, its securities could be delisted, a decision the company would have the right to appeal. The company states it will monitor its share price and consider options to restore compliance.
OSR Holdings, Inc. filed a Definitive Proxy Statement presenting four stockholder proposals and background from its recent business combination with OSR. The Company completed its Business Combination on February 14, 2025, pursuant to amended agreements, and discloses related agreements filed on Form 8-Ks. The proxy asks stockholders to approve (1) election of directors, (2) a non-binding advisory vote on executive compensation, (3) the 2025 Omnibus Incentive Plan with equity sub-plans (including 3,150,000 shares reserved for RSUs and 3,150,000 for options), and (4) Nasdaq 20% Issuance authority to issue up to and exceeding 20% of outstanding common stock under certain pricing conditions. The statement lists directors and executive officers, identifies registered agreements with White Lion, cites forward-looking risk factors, and reports shares outstanding as of August 15, 2025.
OSR Holdings, Inc. entered into two amendments with White Lion Capital, LLC on August 10, 2025, tied to its existing financing arrangements. The company agreed in an amendment to its Note Purchase Agreement to take all necessary actions to convene a stockholder meeting before September 19, 2025 to seek approval for all transactions with White Lion, including issuing securities above the 19.99% Nasdaq Rule 5635 exchange cap and matters under the Equity Line of Credit Agreement dated February 25, 2025. If the company fails to take these actions, it would be in material breach and owe $400,000 in liquidated damages, payable immediately in cash, although simply failing to obtain stockholder approval would not be a breach if the required actions were taken. A parallel amendment to the Common Stock Purchase Warrant clarifies exchange cap provisions and aligns the warrant terms with the note agreement and the equity line.
The preliminary proxy statement for OSR Holdings, Inc. (PRE 14A) sets four proposals for the annual meeting: elect seven directors to the board; approve, on a non-binding advisory basis, named executive officer compensation; adopt share-based incentive sub-plans under a 2025 Omnibus Incentive Plan including RSU and Option sub-plans; and approve, under Nasdaq Listing Rule 5635(d), the ability to issue in one or more non-public offerings shares (or convertible/exercisable securities) that may exceed 20% of outstanding common stock at a price determined as the lower of the Nasdaq Official Closing Price immediately preceding signing or the five-day average prior to signing.
The filing shows 6,300,000 shares remain available for issuance under the Omnibus Plan and lists certain individual beneficial holdings disclosed in the document, including Sang Hoon Kim: 84,020 and Gihyoun Bang: 47,367. The statement also lists director nominees and procedural sections such as voting, proxies and solicitation details.
OSR Holdings, Inc. (OSRH) completed a business combination in February 2025 and reported consolidated assets of $185.4 million and cash of $1.58 million as of June 30, 2025, up from $341,543 at December 31, 2024, including $1,219,888 received from the business combination. Intangible assets, principally patent technology, totaled $155.6 million and goodwill was $26.4 million.
Revenue from the medical-device distribution subsidiary increased to $1.14 million for the quarter, but gross profit fell sharply to $32,782 due to a supplier contract change and inventory returned under a consignment arrangement. Operating loss widened to $(5.23) million for the quarter and net loss for the six months was $(16.62) million, which included approximately $8.5 million of merger-related costs. Current liabilities rose to $15.86 million and a derivative liability of $630,603 was recorded. Recent disclosures include a July 2025 tokenization roadmap with BCM Europe AG and a signed term sheet to acquire Woori IO (noninvasive glucose monitoring), subject to due diligence and milestone-based share issuance.
OSR Holdings, Inc. (Nasdaq: OSRH) filed a Form 8-K to disclose that independent director Sang Hyun Kim resigned from the Board of Directors effective June 26 2025. The company states the resignation "was not the result of any dispute or disagreement" concerning its operations, policies, or practices. No other management changes, financial results, or strategic actions were reported.
- Event date: June 26 2025 (reported July 2 2025)
- Affected position: Independent director seat now vacant
- Reason given: Personal resignation, no disputes cited
No compensatory arrangements, replacement plans, or additional board changes were included in the filing.